Piper Jaffray stays Overweight on Alder Biopharma, Amgen after Novartis filing

Piper Jaffray analyst Christopher Raymond maintains his Overweight rating on Alder Biopharma (ALDR) and Amgen (AMGN) after the filing by Novartis (NVS) alleging legal dispute with the latter about their migraine collaboration. The analyst says that Novartis tried to beat Amgen to the punch after entering agreement with Alder to manufacture eptinezumab, which prompted Amgen to terminate their commercialization agreement. Raymond adds that a resolution of this dispute could take a year or more but believes that investors may conclude that the spat reflects the value of anti-CGRP assets

https://thefly.com/permalinks/entry.php/id2888956/AMGN;NVS;ALDR-Amgen-Novartis-Alder-Biopharmaceuticals-analyst-commentary-at-Piper-Jaffray